Biotheus

Acquired

Zhuhai, China · Founded 2018 · $26.0M raised

Headquarters
Zhuhai
Founded
2018
Total Funding
$26.0M
Last Round
$26.0M Series BMar 2021
Rounds
3
Acquired by
BioNTechFeb 2025

About

Biotheus (普米斯生物技术) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Zhuhai, China, focused on discovering and developing next-generation antibody-based therapeutics for cancer and autoimmune diseases. The company's pipeline centers on bispecific antibodies and related modalities, including its lead asset PM8002 (BNT327), a PD-L1/VEGF bispecific antibody that has advanced into global Phase III clinical trials. Biotheus was acquired by BioNTech in a deal valued at up to approximately $950 million, with the acquisition giving BioNTech full ownership of the BNT327 program targeting multiple tumor types including lung cancer.

Summary

Biotheus is a Life Sciences company based in Zhuhai, China, founded in 2018. It has raised $26.0M in total across 3 rounds, most recently a $26.0M Series B round in Mar 2021. Investors include BioNTech, General Atlantic and IDG Capital.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionFeb 2025
$800.0M

Sign up to see all 4 rounds

Seed through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Biotheus on Indexed.vc
<a href="https://indexed.vc/companies/biotheus"><img src="https://indexed.vc/api/badge/company/biotheus" alt="Biotheus on Indexed.vc" width="260" height="76" /></a>